CD8A and cancer: We have recently demonstrated that cooperation between DC1-driven Th1 cytokines IFN-γ/TNF-α and HER2/neu-targeted antibody trastuzumab is necessary for restoration of MHC class I expression in HER2-overexpressing, but not HER2-low, cancer cells in vitro, thereby facilitating recognition and lysis of these cells by DC1-sensitized HER2-specific CD8+ T-cells.